Prostaglandin E2 Receptor 4 (EP4): A Promising Therapeutic Target for the Treatment of Cancer and Inflammatory Diseases

Author(s): Debasis Das*, Jian Hong

Journal Name: Current Chemical Biology

Volume 15 , Issue 1 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Prostaglandin E2 (PGE2) is involved in several biological processes, including inflammation, pain, fever, renal function, mucosal integrity, angiogenesis and tumor growth. PGE2 receptor subtypes (EP1-4) play pivotal roles in PGE2-mediated biological events. Recent studies revealed the fact that EP4 is commonly upregulated in cancer to stimulate cell proliferation, migration, invasion, and metastasis. Additionally, the EP4 receptor has a role in several anti-inflammatory processes, bone formation and hemostasis. EP4 receptor modulators can be used as drugs of specific interest. A number of EP4 receptor agonists and antagonists are at different stages of clinical development. The agonists of EP4 receptor showed promising results for ulcerative colitis (UC), bone deposition and facilitated bone resorption. The uses of EP4 antagonists, particularly in combination with chemotherapy, endocrine therapy, or immune-based therapies, may be the treatment options for cancer. Several EP4 antagonists are being progressed in clinical trials and hopefully, the results will show the usefulness of EP4 receptor as a target for cancer therapeutics. In this review, we have summarized the EP4 receptor and the possible therapeutic applications of EP4 receptor- selective agonists and antagonists.

Keywords: Prostaglandin, prostaglandin E2, PGE2, EP receptor 4, EP4, EP4 agonist, EP4 antagonist, cancer, inflammation, immunotherapy.

[1]
Marks F, Fürstenberger G, Eds. Prostaglandins, leukotrienes, and other eicosanoids: from biogenesis to clinical application. Weinheim, New York: Wiley-VCH 1999.
[http://dx.doi.org/10.1002/9783527613625]
[2]
Salvado MD, Alfranca A, Haeggström JZ, Redondo JM. Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. Trends Mol Med 2012; 18(4): 233-43.
[http://dx.doi.org/10.1016/j.molmed.2012.02.002] [PMID: 22425675]
[3]
Kawahara K, Hohjoh H, Inazumi T, Tsuchiya S, Sugimoto Y. Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta 2015; 1851(4): 414-21.
[http://dx.doi.org/10.1016/j.bbalip.2014.07.008] [PMID: 25038274]
[4]
Fujino H, Regan JW. Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer? Trends Pharmacol Sci 2003; 24(7): 335-40.
[http://dx.doi.org/10.1016/S0165-6147(03)00162-7] [PMID: 12871665]
[5]
Yang L, Huang Y, Porta R, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006; 66(19): 9665-72.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-1271] [PMID: 17018624]
[6]
Lin C-R, Amaya F, Barrett L, et al. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 2006; 319(3): 1096-103.
[http://dx.doi.org/10.1124/jpet.106.105569] [PMID: 16966471]
[7]
St-Jacques B, Ma W. Prostaglandin E2/EP4 signalling facilitates EP4 receptor externalization in primary sensory neurons in vitro and in vivo. Pain 2013; 154(2): 313-23.
[http://dx.doi.org/10.1016/j.pain.2012.11.005] [PMID: 23265688]
[8]
Tang EHC, Libby P, Vanhoutte PM, Xu A. Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases. J Cardiovasc Pharmacol 2012; 59(2): 116-23.
[http://dx.doi.org/10.1097/FJC.0b013e3182244a12] [PMID: 21697732]
[9]
Majumder M, Xin X, Liu L, Girish GV, Lala PK. Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. Cancer Sci 2014; 105(9): 1142-51.
[http://dx.doi.org/10.1111/cas.12475] [PMID: 24981602]
[10]
Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006; 66(20): 9794-7.
[http://dx.doi.org/10.1158/0008-5472.CAN-06-2067] [PMID: 17047037]
[11]
Fujino H, Regan JW. EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Mol Pharmacol 2006; 69(1): 5-10.
[http://dx.doi.org/10.1124/mol.105.017749] [PMID: 16204467]
[12]
Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 331(7528): 1310-6.
[http://dx.doi.org/10.1136/bmj.331.7528.1310] [PMID: 16322018]
[13]
Bhooshan N, Staats PN, Fulton AM, Feliciano JL, Edelman MJ. Prostaglandin E Receptor EP4 expression, survival and pattern of recurrence in locally advanced NSCLC. Lung Cancer 2016; 101: 88-91.
[http://dx.doi.org/10.1016/j.lungcan.2016.09.011] [PMID: 27794413]
[14]
Burstein SH. The chemistry, biology and pharmacology of the cyclopentenone prostaglandins. Prostaglandins Other Lipid Mediat 2020; 148: 106408.
[http://dx.doi.org/10.1016/j.prostaglandins.2020.106408] [PMID: 31931079]
[15]
Nieves A, Garza LA. Does prostaglandin D2 hold the cure to male pattern baldness? Exp Dermatol 2014; 23(4): 224-7.
[http://dx.doi.org/10.1111/exd.12348] [PMID: 24521203]
[16]
Matsuoka T, Narumiya S. The roles of prostanoids in inflammation, allergy, and immunity. Inflamm Regen 2008; 28: 423-33.
[http://dx.doi.org/10.2492/inflammregen.28.423]
[17]
Hikiji H, Takato T, Shimizu T, Ishii S. The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease. Prog Lipid Res 2008; 47(2): 107-26.
[http://dx.doi.org/10.1016/j.plipres.2007.12.003] [PMID: 18187046]
[18]
Dey I, Lejeune M, Chadee K. Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol 2006; 149(6): 611-23.
[http://dx.doi.org/10.1038/sj.bjp.0706923] [PMID: 17016496]
[19]
Bertagnolli MM, Zauber AG, Solomon S. Prostaglandin inhibition and cardiovascular risk: maybe timing really is everything. Cancer Prev Res (Phila) 2009; 2(3): 195-6.
[http://dx.doi.org/10.1158/1940-6207.CAPR-08-0245] [PMID: 19258547]
[20]
Furuyashiki T, Narumiya S. Roles of prostaglandin E receptors in stress responses. Curr Opin Pharmacol 2009; 9(1): 31-8.
[http://dx.doi.org/10.1016/j.coph.2008.12.010] [PMID: 19157987]
[21]
Konya V, Marsche G, Schuligoi R, Heinemann A. E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther 2013; 138(3): 485-502.
[http://dx.doi.org/10.1016/j.pharmthera.2013.03.006] [PMID: 23523686]
[22]
Yokoyama U, Iwatsubo K, Umemura M, Fujita T, Ishikawa Y. The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev 2013; 65(3): 1010-52.
[http://dx.doi.org/10.1124/pr.112.007195] [PMID: 23776144]
[23]
Zelenay S, van der Veen AG, Böttcher JP, et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell 2015; 162(6): 1257-70.
[http://dx.doi.org/10.1016/j.cell.2015.08.015] [PMID: 26343581]
[24]
Belley A, Chadee K. Prostaglandin E(2) stimulates rat and human colonic mucin exocytosis via the EP(4) receptor. Gastroenterology 1999; 117(6): 1352-62.
[http://dx.doi.org/10.1016/S0016-5085(99)70285-4] [PMID: 10579976]
[25]
Nishigaki N, Negishi M, Honda A, et al. Identification of prostaglandin E receptor ‘EP2’ cloned from mastocytoma cells EP4 subtype. FEBS Lett 1995; 364(3): 339-41.
[http://dx.doi.org/10.1016/0014-5793(95)00421-5] [PMID: 7758593]
[26]
Nishigaki N, Negishi M, Ichikawa A. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol Pharmacol 1996; 50(4): 1031-7.
[PMID: 8863851]
[27]
Sugimoto Y, Narumiya S, Prostaglandin E. Prostaglandin E receptors. J Biol Chem 2007; 282(16): 11613-7.
[http://dx.doi.org/10.1074/jbc.R600038200] [PMID: 17329241]
[28]
Matsuoka T, Narumiya S. Prostaglandin receptor signaling in disease. ScientificWorldJournal 2007; 7: 1329-47.
[http://dx.doi.org/10.1100/tsw.2007.182] [PMID: 17767353]
[29]
Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci 2003; 74(2-3): 143-53.
[http://dx.doi.org/10.1016/j.lfs.2003.09.031] [PMID: 14607241]
[30]
Fujino H, Xu W, Regan JW. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 2003; 278(14): 12151-6.
[http://dx.doi.org/10.1074/jbc.M212665200] [PMID: 12566441]
[31]
Margan D, Borota A, Mracec M, Mracec M. 3D homology model of the human prostaglandin E2 receptor EP4 subtype. Rev Roum Chim 2011; 2012: 39-44.
[32]
Stillman BA, Audoly L, Breyer RM. A conserved threonine in the second extracellular loop of the human EP2 and EP4 receptors is required for ligand binding. Eur J Pharmacol 1998; 357(1): 73-82.
[http://dx.doi.org/10.1016/S0014-2999(98)00522-6] [PMID: 9788776]
[33]
Reader J, Holt D, Fulton A. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 2011; 30(3-4): 449-63.
[http://dx.doi.org/10.1007/s10555-011-9303-2] [PMID: 22002714]
[34]
Terada N, Shimizu Y, Kamba T, et al. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res 2010; 70(4): 1606-15.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-2984] [PMID: 20145136]
[35]
Simper MS, Rundhaug JE, Mikulec C, et al. The tumor promoting activity of the EP4 receptor for prostaglandin E2 in murine skin. Mol Oncol 2014; 8(8): 1626-39.
[http://dx.doi.org/10.1016/j.molonc.2014.06.013] [PMID: 25034079]
[36]
Oh J-M, Kim S-H, Lee Y-I, et al. Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogenesis 2009; 30(1): 141-9.
[http://dx.doi.org/10.1093/carcin/bgn236] [PMID: 18849297]
[37]
Majumder M, Nandi P, Omar A, Ugwuagbo KC, Lala PK. EP4 as a Therapeutic Target for Aggressive Human Breast Cancer. Int J Mol Sci 2018; 19(4): 1019.
[http://dx.doi.org/10.3390/ijms19041019] [PMID: 29596308]
[38]
Kundu N, Ma X, Kochel T, et al. Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties. Breast Cancer Res Treat 2014; 143(1): 19-31.
[http://dx.doi.org/10.1007/s10549-013-2779-4] [PMID: 24281828]
[39]
Take Y, Koizumi S, Nagahisa A, Prostaglandin E. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action. Front Immunol 2020; 11: 324.
[http://dx.doi.org/10.3389/fimmu.2020.00324] [PMID: 32210957]
[40]
Sakata D, Yao C, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, et al. Prostaglandin E Receptor Subtypes EP2 and EP4 Promote TH1 Cell Differentiation and TH17 Cell Expansion Through Different Signaling Modules. Inflamm Res 2009; 58: S244-8.
[http://dx.doi.org/10.1007/BF03354229]
[41]
Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell- mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116(5): 1310-6.
[http://dx.doi.org/10.1172/JCI21404] [PMID: 16670770]
[42]
O’Callaghan G, Houston A. Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? Br J Pharmacol 2015; 172(22): 5239-50.
[http://dx.doi.org/10.1111/bph.13331] [PMID: 26377664]
[43]
Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198(12): 1951-7.
[http://dx.doi.org/10.1084/jem.20030896] [PMID: 14662908]
[44]
Markovič T, Jakopin Ž, Dolenc MS, Mlinarič-Raščan I. Structural features of subtype-selective EP receptor modulators. Drug Discov Today 2017; 22(1): 57-71.
[http://dx.doi.org/10.1016/j.drudis.2016.08.003] [PMID: 27506873]
[45]
Healy MP, Allan AC, Bailey K, Billinton A, Chessell IP, Clayton NM, et al. Discovery of 4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenylacetic acid (GSK726701A), a novel EP 4 receptor partial agonist for the treatment of pain. Bioorg Med Chem Lett 2018; 28: 1892-6.
[http://dx.doi.org/10.1016/j.bmcl.2018.03.091] [PMID: 29636218]
[46]
Watanabe Y, Murata T, Amakawa M, et al. KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. Eur J Pharmacol 2015; 754: 179-89.
[http://dx.doi.org/10.1016/j.ejphar.2015.02.021] [PMID: 25704618]
[47]
Maruyama T, Asada M, Shiraishi T, et al. Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiaPG derivatives with high selectivity. Bioorg Med Chem Lett 2001; 11(15): 2029-31.
[http://dx.doi.org/10.1016/S0960-894X(01)00364-X] [PMID: 11454473]
[48]
Yoshida K, Oida H, Kobayashi T, et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci USA 2002; 99(7): 4580-5.
[http://dx.doi.org/10.1073/pnas.062053399] [PMID: 11917107]
[49]
Kuzumoto Y, Sho M, Ikeda N, et al. Significance and therapeutic potential of prostaglandin E2 receptor in hepatic ischemia/reperfusion injury in mice. Hepatology 2005; 42(3): 608-17.
[http://dx.doi.org/10.1002/hep.20827] [PMID: 16108069]
[50]
Philipose S, Konya V, Sreckovic I, et al. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 2010; 30(12): 2416-23.
[http://dx.doi.org/10.1161/ATVBAHA.110.216374] [PMID: 21071691]
[51]
Tanaka M, Sakai A, Uchida S, et al. Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 2004; 34(6): 940-8.
[http://dx.doi.org/10.1016/j.bone.2004.01.002] [PMID: 15193540]
[52]
Nakagawa K, Imai Y, Ohta Y, Takaoka K. Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone 2007; 41(4): 543-8.
[http://dx.doi.org/10.1016/j.bone.2007.06.013] [PMID: 17681894]
[53]
Maruyama T, Kuwabe S-I, Kawanaka Y, et al. Design and synthesis of a selective EP4-receptor agonist. Part 4: practical synthesis and biological evaluation of a novel highly selective EP4-receptor agonist. Bioorg Med Chem 2002; 10(7): 2103-10.
[http://dx.doi.org/10.1016/S0968-0896(02)00085-8] [PMID: 11983506]
[54]
Nakase H, Fujiyama Y, Oshitani N, et al. Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial. Inflamm Bowel Dis 2010; 16(5): 731-3.
[http://dx.doi.org/10.1002/ibd.21080] [PMID: 19760781]
[55]
Jiang G-L, Nieves A, Im WB, Old DW, Dinh DT, Wheeler L. The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther 2007; 320(1): 22-8.
[http://dx.doi.org/10.1124/jpet.106.111146] [PMID: 17008451]
[56]
Sann H, Erichsen Jv, Hessmann M, Pahl A, Hoffmeyer A. Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice. Life Sci 2013; 92(12): 708-18.
[http://dx.doi.org/10.1016/j.lfs.2013.01.028] [PMID: 23399699]
[57]
Dorich S, Cox JH, Burch JD, et al. Novel pyridone EP4 agonists featuring allylic alcohol ω-chains. Bioorg Med Chem Lett 2020; 30(10): 127104.
[http://dx.doi.org/10.1016/j.bmcl.2020.127104] [PMID: 32201020]
[58]
Billot X, Chateauneuf A, Chauret N, et al. Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg Med Chem Lett 2003; 13(6): 1129-32.
[http://dx.doi.org/10.1016/S0960-894X(03)00042-8] [PMID: 12643927]
[59]
Elworthy TR, Kertesz DJ, Kim W, et al. Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2-Pyrrolidinones-stereochemical and lower side-chain optimization. Bioorg Med Chem Lett 2004; 14(7): 1655-9.
[http://dx.doi.org/10.1016/j.bmcl.2004.01.063] [PMID: 15026044]
[60]
Flesch D, Merk D, Lamers C, Schubert-Zsilavecz M. Novel prostaglandin receptor modulators – Part II: EP receptor modulators; a patent review (2002 – 2012). Expert Opinion on Therapeutic Patents 2013; 23: 233-67.
[61]
Elworthy TR, Brill ER, Chiou S-S, et al. Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents. J Med Chem 2004; 47(25): 6124-7.
[http://dx.doi.org/10.1021/jm049290a] [PMID: 15566283]
[62]
Robert N. Young RN, Billot X, Han Y, et al. Discovery and synthesis of a potent, selective and orally bioavailable EP4 receptor agonist. Heterocycles; 2004.64: 437.
[http://dx.doi.org/10.3987/COM-04-S(P)47]
[63]
Malty RH, Hudmon A, Fehrenbacher JC, Vasko MR. Long-term exposure to PGE2 causes homologous desensitization of receptor- mediated activation of protein kinase A. J Neuroinflammation 2016; 13(1): 181.
[http://dx.doi.org/10.1186/s12974-016-0645-0] [PMID: 27400965]
[64]
Barrett SD, Holt MC, Kramer JB, et al. Difluoromethylene at the γ-Lactam α-Position Improves 11-Deoxy-8-aza-PGE1 Series EP4 Receptor Binding and Activity: 11-Deoxy-10,10-difluoro-8-aza-PGE1 Analog (KMN-159) as a Potent EP4 Agonist. J Med Chem 2019; 62(9): 4731-41.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00336] [PMID: 30964292]
[65]
Owen TA, Patel C, Wei S, et al. KMN-159, a novel EP4 receptor selective agonist, stimulates osteoblastic differentiation in cultured whole rat bone marrow. Gene 2020; 748: 144668.
[http://dx.doi.org/10.1016/j.gene.2020.144668] [PMID: 32334025]
[66]
Hishikari K, Suzuki J, Ogawa M, et al. Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. Cardiovasc Res 2009; 81(1): 123-32.
[http://dx.doi.org/10.1093/cvr/cvn254] [PMID: 18805784]
[67]
Ninomiya T, Hosoya A, Hiraga T, et al. Prostaglandin E(2) receptor EP(4)-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. Eur J Pharmacol 2011; 650(1): 396-402.
[http://dx.doi.org/10.1016/j.ejphar.2010.10.021] [PMID: 20969852]
[68]
Ito M, Nakayama K, Konaka A, Sakata K, Ikeda K, Maruyama T. Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats. Bone 2006; 39(3): 453-9.
[http://dx.doi.org/10.1016/j.bone.2006.02.054] [PMID: 16581323]
[69]
Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohn’s Colitis 2007; 1(1): 10-20.
[http://dx.doi.org/10.1016/j.crohns.2007.06.005] [PMID: 21172179]
[70]
Tanaka K, Suemasu S, Ishihara T, Tasaka Y, Arai Y, Mizushima T. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis. Eur J Pharmacol 2009; 603(1-3): 120-32.
[http://dx.doi.org/10.1016/j.ejphar.2008.11.058] [PMID: 19101538]
[71]
Fujino H. The Roles of EP4 Prostanoid Receptors in Cancer Malignancy Signaling. Biol Pharm Bull 2016; 39(2): 149-55.
[http://dx.doi.org/10.1248/bpb.b15-00840] [PMID: 26830476]
[72]
Chell SD, Witherden IR, Dobson RR, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 2006; 66(6): 3106-13.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-3702] [PMID: 16540660]
[73]
Nakao K, Murase A, Ohshiro H, et al. CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 2007; 322(2): 686-94.
[http://dx.doi.org/10.1124/jpet.107.122010] [PMID: 17495127]
[74]
Machwate M, Harada S, Leu CT, et al. Prostaglandin receptor EP(4) mediates the bone anabolic effects of PGE(2). Mol Pharmacol 2001; 60(1): 36-41.
[http://dx.doi.org/10.1124/mol.60.1.36] [PMID: 11408598]
[75]
Li X, Yang B, Han G, Li W. The EP4 antagonist, L-161,982, induces apoptosis, cell cycle arrest, and inhibits prostaglandin E2-induced proliferation in oral squamous carcinoma Tca8113 cells. J Oral Pathol Med 2017; 46(10): 991-7.
[http://dx.doi.org/10.1111/jop.12572] [PMID: 28342204]
[76]
Sutton J, Clark DE, Higgs C, et al. From virtual to clinical: The discovery of PGN-1531, a novel antagonist of the prostanoid EP4 receptor. Bioorg Med Chem Lett 2014; 24(9): 2212-21.
[http://dx.doi.org/10.1016/j.bmcl.2014.02.068] [PMID: 24703233]
[77]
Hattori K, Tanaka A, Fujii N, et al. Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. J Med Chem 2005; 48(9): 3103-6.
[http://dx.doi.org/10.1021/jm050085k] [PMID: 15857112]
[78]
Wilson RJ, Giblin GMP, Roomans S, Rhodes SA, Cartwright K-A, Shield VJ. GW627368X ((N-2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist: GW627368X: EP4 receptor antagonist. Br J Pharmacol 2009; 148: 326-39.
[http://dx.doi.org/10.1038/sj.bjp.0706726] [PMID: 16604093]
[79]
Clark P, Rowland SE, Denis D, Mathieu M-C, Stocco R, Poirier H. MF498 [ N -[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7 H -pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl-2-(2-methoxyphenyl)acetamide], a Selective E Prostanoid Receptor 4 Antagonist, Relieves Joint Inflammation and Pain in Rodent Models of Rheumatoid and Osteoarthritis. J Pharmacol Exp Ther 2008; 325: 425-34.
[http://dx.doi.org/10.1124/jpet.107.134510] [PMID: 18287210]
[80]
Molinaro C, Gauvreau D, Hughes G, et al. Remote electronic control in the regioselective reduction of succinimides: a practical, scalable synthesis of Ep4 antagonist MF-310. J Org Chem 2009; 74(17): 6863-6.
[http://dx.doi.org/10.1021/jo901267x] [PMID: 19663395]
[81]
Burch JD, Belley M, Fortin R, et al. Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor. Bioorg Med Chem Lett 2008; 18(6): 2048-54.
[http://dx.doi.org/10.1016/j.bmcl.2008.01.103] [PMID: 18291643]
[82]
Burch JD, Farand J, Colucci J, et al. Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor. Bioorg Med Chem Lett 2011; 21(3): 1041-6.
[http://dx.doi.org/10.1016/j.bmcl.2010.12.014] [PMID: 21215624]
[83]
Blouin M, Han Y, Burch J, Farand J, Mellon C, Gaudreault M. The Discovery of 4-1-[(2,5-Dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl-carbonyl)amino]cyclopropylbenzoic Acid(MK-2894), A potent and selective prostaglandin E 2 subtype 4 receptor antagonist. J Med Chem 2010; 53: 2227-38..
[http://dx.doi.org/10.1021/jm901771h] [PMID: 20163116]
[84]
Colucci J, Boyd M, Berthelette C, Chiasson J-F, Wang Z, Ducharme Y. Discovery of 4-1-[(1-[4-(trifluoromethyl)benzyl]-1H-indol-7-ylcarbonyl)amino]cyclopropylbenzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. Bioorg Med Chem Lett 2010; 20: 3760-3.
[http://dx.doi.org/10.1016/j.bmcl.2010.04.065] [PMID: 20471829]
[85]
Murase A, Taniguchi Y, Tonai-Kachi H, Nakao K, Takada J. In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist. Life Sci 2008; 82(3-4): 226-32.
[http://dx.doi.org/10.1016/j.lfs.2007.11.002] [PMID: 18155068]
[86]
Murase A, Okumura T, Sakakibara A, Tonai-Kachi H, Nakao K, Takada J. Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation. Eur J Pharmacol 2008; 580(1-2): 116-21.
[http://dx.doi.org/10.1016/j.ejphar.2007.10.054] [PMID: 18031725]
[87]
Ma X, Holt D, Kundu N, et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis. OncoImmunology 2013; 2(1): e22647.
[http://dx.doi.org/10.4161/onci.22647] [PMID: 23482441]
[88]
Schiffler MA, Chandrasekhar S, Fisher MJ, et al. Discovery and characterization of a potent and selective EP4 receptor antagonist. Bioorg Med Chem Lett 2015; 25(16): 3176-8.
[http://dx.doi.org/10.1016/j.bmcl.2015.05.091] [PMID: 26091726]
[89]
Okumura Y, Yamagishi T, Nukui S, Nakao K. Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. Bioorg Med Chem Lett 2017; 27(5): 1186-92.
[http://dx.doi.org/10.1016/j.bmcl.2017.01.067] [PMID: 28169162]
[90]
Xu S, Zhang Z, Ogawa O, et al. An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer. Cell Biochem Biophys 2014; 70(1): 521-7.
[http://dx.doi.org/10.1007/s12013-014-9951-2] [PMID: 24744183]
[91]
Hoshino T, Namba T, Takehara M, et al. Improvement of cognitive function in Alzheimer’s disease model mice by genetic and pharmacological inhibition of the EP(4) receptor. J Neurochem 2012; 120(5): 795-805.
[http://dx.doi.org/10.1111/j.1471-4159.2011.07567.x] [PMID: 22044482]
[92]
Boyd MJ, Berthelette C, Chiasson J-F, et al. A novel series of potent and selective EP(4) receptor ligands: facile modulation of agonism and antagonism. Bioorg Med Chem Lett 2011; 21(1): 484-7.
[http://dx.doi.org/10.1016/j.bmcl.2010.10.106] [PMID: 21126875]
[93]
Caselli G, Bonazzi A, Lanza M, et al. Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug. Arthritis Res Ther 2018; 20(1): 39.
[http://dx.doi.org/10.1186/s13075-018-1537-8] [PMID: 29490676]
[94]
Albu DI, Wang Z, Huang K-C, et al. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. OncoImmunology 2017; 6(8): e1338239.
[http://dx.doi.org/10.1080/2162402X.2017.1338239] [PMID: 28920002]
[95]
Yang J-J, Yu W-W, Hu L-L, et al. Discovery and Characterization of 1H-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy. J Med Chem 2020; 63(2): 569-90.
[http://dx.doi.org/10.1021/acs.jmedchem.9b01269] [PMID: 31855426]
[96]
Blanco M-J, Vetman T, Chandrasekhar S, et al. Discovery of substituted-2,4-dimethyl-(naphthalene-4-carbonyl)amino-benzoic acid as potent and selective EP4 antagonists. Bioorg Med Chem Lett 2016; 26(1): 105-9.
[http://dx.doi.org/10.1016/j.bmcl.2015.11.023] [PMID: 26608552]
[97]
Bäurle S, Nagel J, Peters O, et al. Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis. J Med Chem 2019; 62(5): 2541-63.
[http://dx.doi.org/10.1021/acs.jmedchem.8b01862] [PMID: 30707023]
[98]
Masuko K, Murata M, Yudoh K, et al. Prostaglandin E2 regulates the expression of connective tissue growth factor (CTGF/CCN2) in human osteoarthritic chondrocytes via the EP4 receptor. BMC Res Notes 2010; 3: 5.
[http://dx.doi.org/10.1186/1756-0500-3-5] [PMID: 20205862]
[99]
Yao C, Sakata D, Esaki Y, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 2009; 15(6): 633-40.
[http://dx.doi.org/10.1038/nm.1968] [PMID: 19465928]
[100]
McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 2002; 110(5): 651-8.
[http://dx.doi.org/10.1172/JCI0215528] [PMID: 12208866]
[101]
Okumura T, Murata Y, Taniguchi K, Murase A, Nii A. Effects of the selective EP4 antagonist, CJ-023,423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis. J Pharm Pharmacol 2008; 60(6): 723-30.
[http://dx.doi.org/10.1211/jpp.60.6.0007] [PMID: 18498708]
[102]
Kabashima K, Saji T, Murata T, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002; 109(7): 883-93.
[http://dx.doi.org/10.1172/JCI0214459] [PMID: 11927615]
[103]
Hristovska A-M, Rasmussen LE, Hansen PBL, et al. Prostaglandin E2 induces vascular relaxation by E-prostanoid 4 receptor- mediated activation of endothelial nitric oxide synthase. Hypertension 2007; 50(3): 525-30.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.088948] [PMID: 17635857]
[104]
Konya V, Üllen A, Kampitsch N, et al. Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking. J Allergy Clin Immunol 2013; 131(2): 532-40.e1, 2.
[http://dx.doi.org/10.1016/j.jaci.2012.05.008] [PMID: 22704539]
[105]
Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002; 62(1): 28-32.
[PMID: 11782353]
[106]
Chuang YC, Tyagi P, Huang CC, Chancellor MB, Yoshimura N. Mechanisms and urodynamic effects of a potent and selective EP4 receptor antagonist, MF191, on cyclophosphamide and prostaglandin E2-induced bladder overactivity in rats. BJU Int 2012; 110(10): 1558-64.
[http://dx.doi.org/10.1111/j.1464-410X.2012.11096.x] [PMID: 22452546]
[107]
Holt DM, Ma X, Kundu N, Collin PD, Fulton AM. Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother 2012; 35(2): 179-88.
[http://dx.doi.org/10.1097/CJI.0b013e318247a5e9] [PMID: 22306906]
[108]
Arber N, DuBois RN. Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr Gastroenterol Rep 1999; 1(5): 441-8.
[http://dx.doi.org/10.1007/s11894-999-0027-1] [PMID: 10980984]
[109]
Takahashi T, Ichikawa H, Morimoto Y, Tsuneyama K, Hijikata T. Inhibition of EP2/EP4 prostanoid receptor-mediated signaling suppresses IGF-1-induced proliferation of pancreatic cancer BxPC-3 cells via upregulating γ-glutamyl cyclotransferase expression. Biochem Biophys Res Commun 2019; 516(2): 388-96.
[http://dx.doi.org/10.1016/j.bbrc.2019.06.054] [PMID: 31217077]
[110]
Bhattacharjee RN, Timoshenko AV, Cai J, Lala PK. Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer. Cancer Sci 2010; 101(9): 2026-32.
[http://dx.doi.org/10.1111/j.1349-7006.2010.01647.x] [PMID: 20608938]
[111]
Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest 2012; 92(8): 1115-28.
[http://dx.doi.org/10.1038/labinvest.2012.90] [PMID: 22641101]
[112]
Nandi P, Girish GV, Majumder M, Xin X, Tutunea-Fatan E, Lala PK. PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells. BMC Cancer 2017; 17(1): 11.
[http://dx.doi.org/10.1186/s12885-016-3018-2] [PMID: 28056899]
[113]
Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010; 251(3): 499-505.
[http://dx.doi.org/10.1097/SLA.0b013e3181cc939f] [PMID: 20134314]
[114]
Lanza M, Caselli G, Ferrari F, Grotti A, Cavagnoli R, Perrella M. TTHU0085 Cr6086, a novel ep4 antagonist with immunomodulatory properties, decreases bone loss in the rat collagen-induced arthritis (CIA) model: a microtomography (MICROCT) study. BMJ Publishing Group Ltd and European League Against Rheumatism . 2018; pp. 265-5.
[http://dx.doi.org/10.1136/annrheumdis-2018-eular.2402]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2021
Published on: 21 December, 2020
Page: [50 - 68]
Pages: 19
DOI: 10.2174/2212796814999201222101310
Price: $25

Article Metrics

PDF: 105
HTML: 2